Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06299813
Other study ID # 771.284
Secondary ID 2022-002955-20
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 20, 2024
Est. completion date April 1, 2026

Study information

Verified date March 2024
Source A.O.U. Città della Salute e della Scienza
Contact Claudia Bondone, MD
Phone +390113131611
Email cbondone@cittadellasalute.to.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this double-blind, Placebo-controlled Randomized Study is to assess if a single dose of betamethasone in children with febrile adenoviral infection works well in achieving an early fever regulation. The experimentation is conducted to answer this question: "Can betamethasone help reduce fever more quickly in a child with viral adenovirus infection? "The secondary objective is to assess if the child's overall clinical conditions improve more rapidly (reduced sore throat, quicker return to regular eating) and a reduction in the incidence and duration of hospitalizations.


Description:

Adenovirus pharyngitis is a highly febrile illness and tends to last for up to 5-7 days if treated only with antipyretics. Currently, there are no evidence-based effective treatments for this infection. The use of single-dose betamethasone is believed to be effective in significantly reducing the hyper-inflammation that the virus can induce in pediatric patients. However, it is an empirical therapeutic practice used variably because positive clinical experience encourages its prescription but lacks experimental evidence. The main question at hand is whether the single administration of betamethasone at a dosage of 0.1 mg/kg is truly effective in symptomatic adenoviral infection and whether it can, therefore, reduce the overall fever duration and improve the clinical condition of the children. The study does not involve changes to current clinical practice but aims to demonstrate that this clinical practice, mostly used empirically, is actually based on scientific evidence.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date April 1, 2026
Est. primary completion date January 15, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Months to 6 Years
Eligibility Inclusion Criteria: - Body Temperature measured with an axillary or ear thermometer >= n 37.5°C, persisting for a minimum of 6 hours and a maximum of 5 days. - Clinical presentation consistent with pharyngo-tonsillar infection by Adenovirus, including At least one of the following symptoms: pharyngodonidae /asthenia/nausea/vomiting/diarrhea/cough/rhinorrhea/abdominal pain/otalgia and at least one of the following signs: pharyngeal hyperemia with or without pharyngo-tonsillar exudate/inflammation of the upper or lower airways/lymphadenopathy/skin rash.- - Positive result on the antigen test for Adenovirus performed with the "Biosensor" rapid swab. - Negative result on the swab for Group A Streptococcus (SBEGA), if deemed necessary following McIsaac criteria - Informed consent form for participation in the study signed by the parent(s) or legal guardian. Exclusion Criteria: - Adequate dosage of betamethasone in the 48 hours prior. - Underlying chronic illness associated with an increased risk of unusual or severe adenoviral infection. - Inability to tolerate oral medications. - Documented allergy or any other known contraindication to Bentelan 0.5mg® medication.-Patients on chronic therapy with anticholinesterases, salicylates, nonsteroidal anti-inflammatory drugs, thiazides, furosemide, amphotericin, xanthines (theophylline), antidiabetic drugs, insulin, cyclosporine, ritonavir, ketoconazole, acetylsalicylic acid, phenytoin, phenobarbital, ephedrine, rifampicin, anticoagulants. - Subacute or chronic conditions requiring a higher equivalent dose of betamethasone or known primary or secondary adrenal insufficiency. - Transfer to another hospital for any reason. - Parents who are unable to understand the proposed study or cannot reliably participate in phone follow-up due to significant language barriers. - Participation in another study involving an experimental drug within the 30 days prior to and during the current study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bentelan
The experimental treatment group will be administered betamethasone 0.1 mg per kg.
Placebo
The placebo used in the study will consist of 100 ml of purified water (PPI BBU).

Locations

Country Name City State
Italy Ospedale Infantile Regina Margherita Torino

Sponsors (1)

Lead Sponsor Collaborator
A.O.U. Città della Salute e della Scienza

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with a sustained fever resolution at 24 hours from randomization The proportion of patients achieving sustained fever resolution at 24 hours from is the proportion of patients with a a body temperature <37.5°C at 18 and 24 hours from randomization. at 18 and 24 hours from randomization
Secondary Pharyngeal-tonsillar pain level in patients younger than 36 months According to the patient age, the pharyngeal-tonsillar pain level of the child will be measured by the FLACC (Face, Legs, Activity, Cry, Consolability) scale in patients younger than 36 months.
FLACC mean value 5 points on ten.
from the date of randomization, up to 72 hours
Secondary Hospitalization The proportion of patients admitted following emergency access. from date of randomization until the date of discharge from emergency department, up to 72 hours
Secondary Duration of hospitalization (among those hospitalized), measured in days Number of days from admission date to discharge date. from date of randomization until the date of discharge,up to 72 hours
Secondary Cumulative incidence of fever resolution Cumulative incidence of fever resolution is measured from randomization until the fever resolution confirmed by measurement at the subsequent timepoint; patients without fever resolution within the time of the last fever assessment are censored at this time. from date of randomization to 72 hours from randomization
Secondary Fever duration Time from randomization until the first measurement with Body Temperature<37.5°C from date of randomization until 72 hours from randomization
Secondary Pharyngeal-tonsillar pain level in patients older than 36 months According to the patient's age, the pharyngeal-tonsillar pain level of the child was measured by the Faces Pain Rating Scale (Wong-Baker Scale) in patients with age more or equal to 36 months. from the date of randomization, up to 72 hours
See also
  Status Clinical Trial Phase
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Recruiting NCT03665675 - Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Early Phase 1
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Recruiting NCT03266627 - Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Phase 2
Not yet recruiting NCT03325517 - Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Completed NCT04056546 - Interest of Rapid Typing in Adenovirus Infections.
Withdrawn NCT00448994 - Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients N/A
Enrolling by invitation NCT06027879 - Anti-viral T-cell Therapy by Gamma Capture Phase 1/Phase 2
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Terminated NCT02420080 - A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Completed NCT01535885 - Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV Phase 1
Terminated NCT03339401 - The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation Phase 2
Withdrawn NCT01584037 - Adenovirus Vaccine Pregnancy Registry N/A
Withdrawn NCT03532035 - Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia Phase 2
Recruiting NCT02008812 - Ad Sensor-based Real-time Diagnosis of Adenovirus N/A
Active, not recruiting NCT04364178 - Viral Specific T-Lymphocytes to Treat Adenovirus or CMV Phase 1/Phase 2
Recruiting NCT05664126 - Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation Phase 2